Targeting the CaN/FoxO1/FABP4 Pathway in SERCA2 Dysfunction-Induced Atherosclerosis

Study Background and Research Question

Atherosclerosis, a chronic inflammatory disease marked by plaque accumulation in arterial walls, is a primary cause of cardiovascular morbidity and mortality. Central to its pathogenesis is the formation of lipid-laden foam cells from macrophages, driven by disrupted lipid metabolism and persistent inflammation. Recent advances have emphasized the importance of intracellular lipid trafficking proteins—including fatty acid binding protein 4 (FABP4)—in mediating these processes. However, the upstream regulatory signals that control FABP4 expression and foam cell formation, particularly in the context of endoplasmic reticulum (ER) stress and calcium handling, remain incompletely defined.

This study, led by Tong et al., directly addresses whether dysfunction of sarcoplasmic/endoplasmic reticulum Ca²⁺ ATPase 2 (SERCA2)—specifically, the C674S mutation—accelerates atherosclerosis by modulating the calcineurin (CaN)/forkhead box O1 (FoxO1)/FABP4 pathway and promoting pathological foam cell formation (see summary).

Key Innovation from the Reference Study

The principal innovation lies in elucidating a mechanistic axis—CaN/FoxO1/FABP4—that connects SERCA2 dysfunction with foam cell formation and atherosclerotic lesion progression. Prior work implicated ER stress in atherogenesis, but this study defines a specific, targetable molecular pathway: SERCA2 C674S mutation enhances calcineurin activity and nuclear FoxO1 translocation, upregulating FABP4 expression. Critically, pharmacological or genetic inhibition of FABP4 interrupts this maladaptive lipid metabolic cascade, thereby curtailing foam cell generation and atherogenesis (internal review).

Methods and Experimental Design Insights

To dissect the causal pathway, the authors utilized heterozygous SERCA2 C674S knock-in (SKI) mice as a model of SERCA2 dysfunction. They compared SKI and wild-type littermates through a combination of:

• Serum metabolomic profiling to detect systemic metabolic alterations.
• Histological analyses of the aorta and aortic root for lesion characterization.
• Isolation of bone marrow-derived macrophages (BMDMs) for in vitro studies of lipid uptake, protein expression, and foam cell quantification.
• Pharmacological interventions targeting FoxO1 and FABP4 (including use of BMS 309403) to interrogate pathway involvement.
• Genetic reduction of FABP4 (partial knockout) to evaluate its necessity in disease progression.

The study employed robust controls and quantitative endpoints, such as immunoblotting for pathway proteins, Oil Red O staining for lipid accumulation, and morphometry for atherosclerotic plaque burden (related article).

Core Findings and Why They Matter

The data demonstrate that SERCA2 C674S mutation in macrophages induces calcineurin activity and FoxO1 nuclear localization, which in turn upregulates FABP4 transcription. This molecular sequence enhances fatty acid synthesis and uptake, promoting foam cell formation—a critical driver of atherosclerotic lesion expansion. Notably, targeted inhibition of the pathway at the levels of FoxO1 or FABP4, either pharmacologically (e.g., with BMS 309403) or genetically, normalized lipid metabolism and suppressed foam cell formation in SKI BMDMs. In vivo, these interventions significantly reduced atherosclerotic plaque area in affected mice (mechanistic analysis).

These findings clarify the pathophysiological role of FABP4 in connecting ER calcium dysregulation with inflammatory lipid accumulation. The results position FABP4 as a nodal point for intervention, with direct implications for designing more precise therapeutic studies targeting atherosclerosis and related metabolic diseases.

Comparison with Existing Internal Articles

Several recent reviews and original research articles corroborate the centrality of the CaN/FoxO1/FABP4 axis in atherogenesis. For example, a mechanistic summary (Targeting the CaN/FoxO1/FABP4 Pathway to Prevent Foam Cell Formation in Atherosclerosis) emphasizes how SERCA2 dysfunction, via this pathway, amplifies foam cell formation. Another article (BMS 309403: FABP4 Inhibitor for Atherosclerosis Research) highlights the experimental use of BMS 309403 to dissect lipid metabolism and inflammation in macrophage-driven models. The current reference study builds upon these observations by providing direct genetic and pharmacological evidence—rather than correlative association—that FABP4 is a key modulator in this context. The consistency across these resources strengthens confidence in FABP4 as a mechanistic and experimental target.

Limitations and Transferability

Despite its strengths, the study has inherent limitations. The reliance on a specific mouse knock-in model (SERCA2 C674S) may limit generalizability to all contexts of ER stress or calcium dysregulation in humans. Most interventions were acute or subchronic, leaving open questions about long-term safety and efficacy of FABP4 inhibition. Furthermore, while BMDMs are a validated model for foam cell formation, in vivo complexity—including contributions from other cell types or systemic metabolic changes—may modify outcomes.

Transferability to human disease will require further validation in clinical or translational models, particularly to assess potential off-target effects and to confirm that FABP4 inhibition does not adversely affect physiological lipid handling elsewhere in the body.

Protocol Parameters

• Mouse model: Heterozygous SERCA2 C674S knock-in (SKI) mice; controls are wild-type littermates.
• BMDM isolation: Standard protocols for bone marrow extraction and differentiation to macrophages.
• Pharmacological inhibition: BMS 309403 used at concentrations ranging from 1–25 μM in cell culture studies (see product information); working solutions prepared in DMSO.
• Foam cell assessment: Oil Red O staining and quantification of lipid-laden macrophages.
• Histology: Aorta and aortic root fixed, sectioned, and stained for lesion quantification.
• Western blotting: Used to detect expression and nuclear localization of FoxO1, FABP4, and calcineurin.
• Genetic perturbation: Partial FABP4 deficiency generated by heterozygous knockout breeding.

Research Support Resources

For researchers seeking to recapitulate or extend these findings, BMS 309403 (SKU B7794) is a well-characterized, potent, and selective FABP4 inhibitor suitable for in vitro and in vivo studies. The compound is DMSO-soluble and recommended for use at 1–25 μM in cell-based assays, with detailed handling instructions available in the APExBIO product dossier. This reagent supports exploration of FABP4’s role in lipid metabolism, inflammation, and metabolic disease models. Proper storage and solubilization protocols maximize experimental reproducibility and reliability. APExBIO provides additional technical support for workflow optimization in cardiovascular and metabolic disease research.